Form 4: Nuvalent's Chief Development Officer, Darlene Noci, Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Darlene Noci, Chief Development Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock on March 27, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Darlene Noci, the Chief Development Officer of Nuvalent, Inc., executed transactions involving the company's Class A Common Stock on March 27, 2025.
- Noci exercised stock options to acquire 2,227 shares at $18.93 and 1,773 shares at $14.40.
- Simultaneously, Noci sold 3,100 shares at an average price of $72.91 and 900 shares at an average price of $73.83.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024.
- Following these transactions, Noci directly owns 48,034 shares of Class A Common Stock.
- Noci also holds options to purchase 33,573 shares at $18.93 and 27,388 shares at $14.40.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of insider trading activity under a pre-arranged plan. There's no indication of positive or negative implications for the company.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and provide transparency into their trading activities. The use of a 10b5-1 plan suggests a pre-arranged strategy for managing equity positions.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a form of long-term incentive.
- Rule 10b5-1 trading plans are a common practice among corporate insiders to manage their stock holdings while avoiding accusations of insider trading.
- The vesting schedules of the options are typical, with a portion vesting initially and the remainder vesting over several years.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by a company officer, but the existence of a 10b5-1 plan mitigates concerns.
Key Dates
| Date | Description |
|---|---|
| 2023-01-04 | 25% of the shares underlying one stock option vested on this date. |
| 2023-08-01 | 25% of the shares underlying another stock option vested on this date. |
| 2024-11-18 | The reporting person adopted a Rule 10b5-1 trading plan on this date. |
| 2025-03-27 | Date of the reported transactions: exercising stock options and selling shares. |
| 2025-03-28 | Date of the Form 4 filing. |
| 2032-01-04 | Expiration date of one of the stock options. |
| 2032-08-01 | Expiration date of the other stock option. |
Keywords
Nuvalent, NUVL, Darlene Noci, Chief Development Officer, Stock Options, Class A Common Stock, Form 4, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.